Pacific Biosciences Of California (PACB) Capital Expenditures (2010 - 2026)

Pacific Biosciences Of California's Capital Expenditures history runs 17 years deep, the most recent figure standing at $3.0 million for Q1 2026.

• On a quarterly basis, Capital Expenditures rose 119.08% year-over-year to $3.0 million in Q1 2026; TTM through Mar 2026 was $4.4 million, a 18.12% increase from a year earlier, with the FY2025 full-year figure at $2.7 million, down 56.14% from the prior year.
• Capital Expenditures improved to $3.0 million in Q1 2026 per PACB's latest filing, from $861000.0 in the prior quarter.
• Across five years, Capital Expenditures topped out at $4.9 million in Q4 2022 and bottomed at -$787000.0 in Q3 2024.
• The 5-year median for Capital Expenditures is $2.0 million (2023), against an average of $2.2 million.
• Across the five-year window, Capital Expenditures soared 807.23% in 2022 and tumbled 194.82% in 2024, its largest moves.
• Year by year, Capital Expenditures stood at $4.9 million in 2022, then plunged by 58.73% to $2.0 million in 2023, then decreased by 20.11% to $1.6 million in 2024, then plunged by 46.75% to $861000.0 in 2025, then soared by 253.43% to $3.0 million in 2026.
• Per Business Quant, the three latest PACB Capital Expenditures figures stand at $3.0 million (Q1 2026), $861000.0 (Q4 2025), and -$86000.0 (Q3 2025).